Search results
Results from the WOW.Com Content Network
An experimental drug is a medicinal product (a drug or vaccine) that has not yet received approval from governmental regulatory authorities for routine use in human or veterinary medicine. A medicinal product may be approved for use in one disease or condition but still be considered experimental for other diseases or conditions.
Experimental drugs for Alzheimer's disease (1 C, 20 P) Experimental gene therapies (22 P) Experimental monoclonal antibodies (53 P) Experimental non-hallucinogens (11 P)
Right-to-try laws are United States state laws and a federal law that were created with the intent of allowing terminally ill patients access to experimental therapies (drugs, biologics, devices) that have completed Phase I testing but have not been approved by the Food and Drug Administration (FDA). Prior to the passage of right to try laws ...
Experimental cancer treatments are normally available only to people who participate in formal research programs, which are called clinical trials. Occasionally, a seriously ill person may be able to access an experimental drug through an expanded access program. Some of the treatments have regulatory approval for treating other conditions.
The United States Food and Drug Administration's Investigational New Drug (IND) program is the means by which a pharmaceutical company obtains permission to start human clinical trials and to ship an experimental drug across state lines (usually to clinical investigators) before a marketing application for the drug has been approved.
By October 2014, the United States Food and Drug Administration had approved the use of several experimental drugs, including ZMapp, to be used on patients infected with Ebola virus. The use of such drugs during the epidemic was also deemed ethical by the World Health Organization (WHO). [ 23 ]
Blarcamesine (developmental code name ANAVEX 2-73) is an experimental drug which is under development for the treatment of Alzheimer's disease and a variety of other indications. [1] Blarcamesine acts as an agonist of the sigma σ 1 receptor, the muscarinic acetylcholine M 1 receptor, and the ionotropic glutamate NMDA receptor. [2] [1]
Pages in category "Experimental cancer drugs" The following 200 pages are in this category, out of approximately 262 total. This list may not reflect recent changes.